Back to Search Start Over

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.

Authors :
Churchman ML
Low J
Qu C
Paietta EM
Kasper LH
Chang Y
Payne-Turner D
Althoff MJ
Song G
Chen SC
Ma J
Rusch M
McGoldrick D
Edmonson M
Gupta P
Wang YD
Caufield W
Freeman B
Li L
Panetta JC
Baker S
Yang YL
Roberts KG
McCastlain K
Iacobucci I
Peters JL
Centonze VE
Notta F
Dobson SM
Zandi S
Dick JE
Janke L
Peng J
Kodali K
Pagala V
Min J
Mayasundari A
Williams RT
Willman CL
Rowe J
Luger S
Dickins RA
Guy RK
Chen T
Mullighan CG
Source :
Cancer cell [Cancer Cell] 2015 Sep 14; Vol. 28 (3), pp. 343-56. Date of Electronic Publication: 2015 Aug 27.
Publication Year :
2015

Abstract

Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.<br /> (Copyright © 2015 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1878-3686
Volume :
28
Issue :
3
Database :
MEDLINE
Journal :
Cancer cell
Publication Type :
Academic Journal
Accession number :
26321221
Full Text :
https://doi.org/10.1016/j.ccell.2015.07.016